- Ziwig Endotest® is an in vitro diagnostic device for professional use in the diagnosis of endometriosis using a saliva sample.
- Ziwig Endotest® is an innovative diagnostic method based on the analysis of salivary miRNA and the identification of phenotypic profiles characteristic of endometriosis identified by NGS (next-generation sequencing) and modelled by AI.
- This in vitro diagnostic medical device is a regulated health product and, in accordance with these regulations, bears the CE mark.
Please read the information supplied with Ziwig Endotest® carefully. Manufacturer: Ziwig. Last update : 09/2024 - Ziwig Endotest® has obtained CE certification from a notified body (2797).
Investing in diagnostic innovation
in women’s health
Ziwig : expertise and advances in biotechnology for women’s health
Ziwig is a global leader in biotechnology, dedicated to advancing women’s health.
Our cutting-edge diagnostic technology leverages the power of salivary RNA analysis,
combining next-generation sequencing (NGS) with artificial intelligence to deliver groundbreaking solutions.
Our product
Ziwig Endotest® : a diagnostic
solution for endometriosis
Ziwig Endotest® is the first-ever biological test specifically designed to diagnose endometriosis, significantly reducing the time required to identify this condition.
This groundbreaking innovation aims to enhance patient care, safeguard fertility, and streamline treatment pathways for improved outcomes.
Validated by the French National Health Authority (HAS), Ziwig Endotest® benefits from an early access procedure, a guarantee of its innovation and relevance to the healthcare system.
An International scientific recognition
Our technology has earned acclaim from the international scientific community, exemplified by the prestigious Prix Galien International 2024, which honors groundbreaking achievements in medical innovation.
Our research is consistently featured in leading scientific journals, including the NEJM Evidence.
Research and development
pipeline
Ziwig’s groundbreaking research goes beyond endometriosis, with ongoing projects exploring other female pathologies, certain gynecological cancers, and neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS).
Opportunities
for growth and expansion
Ziwig is experiencing rapid expansion, with revenue projections set to begin in 2025.
Our unique positioning within a dynamic and fast-evolving technology sector, reinforced by prestigious medical accolades, empowers us to address global demands for early diagnosis and advancements in molecular biology.
Be part of a strong and future-focused vision
We invite investors who align with our vision of responsible innovation and meaningful social impact.
By supporting Ziwig, you help advance groundbreaking diagnostic tools that transform women’s health
and make a lasting difference.
Get in touch
Contact us by filling in this form
Stay connected
Sign up to be notified of the latest news and publications.
